欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Mal-PEG2-VCP-Eribulin_2130869-18-8_产品详情
2130869-18-8
  • Mal-PEG2-VCP-Eribulin

  • names:

    Mal-PEG2-VCP-Eribulin

  • CAS号:

    2130869-18-8

    MDL Number:
  • MF(分子式): C70H99N7O21 MW(分子量): 1374.57
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Mal-PEG2-VCP-Eribulin
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM001057-5mg 5mg 95.75% ¥ 114750.00 ¥ 114750.00 2-3天
- +
¥ 0.00
YZM001057-1mg 1mg 95.75% ¥ 32500.00 ¥ 32500.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 2130869-18-8
Inchi
InchiKey
分子式 Formula C70H99N7O21
分子量 Molecular Weight 1374.57
溶解度Solubility
性状
储藏条件 Storage conditions 4°C,In solvent : -80°C, 6 months月; -20°C, 1 month月 (protect from light, stored under nitrogen)
Mal-PEG2-VCP-Eribulin(CAS:2130869-18-8)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin
IntroductionMalEG2CPribulin consists the ADCs linker (MalEG2CP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. MalEG2CPribulin is an Eribulinased drug for antibody conjugates.
Application1
Application2
Application3
Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates[1].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.
【2】.Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents